PriceTargets.com logo

Constellation Pharmaceuticals - CNST Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$33.99 As of 07/15/2021 01:00 AM ET
+0 (0.00%)
Get New Constellation Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNST

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Constellation Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $33.99.

This chart shows the closing price for CNST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Constellation Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/17/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$50.00 ➝ $34.00Low
6/4/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$33.00 ➝ $34.00Low
6/3/2021Truist FinancialLower TargetBuy ➝ Hold$50.00 ➝ $34.00Low
6/3/2021Truist FinancialDowngradeBuy ➝ HoldLow
6/3/2021CowenDowngradeOutperform ➝ Market PerformMedium
6/2/2021BMO Capital MarketsDowngradeMarket PerformMedium
6/2/2021Robert W. BairdDowngradeOutperform ➝ NeutralMedium
6/2/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$34.00Medium
4/7/2021Royal Bank of CanadaReiterated RatingBuy$50.00Low
1/25/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$27.00 ➝ $50.00Low
9/24/2020OppenheimerReiterated RatingHold$20.00Low
9/8/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
9/3/2020Brookline Capital ManagementInitiated CoverageBuy$33.00Low
8/9/2020Jefferies Financial GroupReiterated RatingBuyLow
8/6/2020BMO Capital MarketsLower TargetMarket Perform$34.00 ➝ $28.00Medium
8/6/2020OppenheimerLower TargetOutperform$55.00 ➝ $47.00High
8/6/2020HC WainwrightReiterated RatingBuyMedium
7/20/2020Jefferies Financial GroupLower TargetBuy$63.00 ➝ $53.00Low
6/24/2020JMP SecuritiesInitiated CoverageMarket Perform$36.00Low
6/15/2020BMO Capital MarketsLower TargetMarket Perform$42.00 ➝ $34.00High
6/8/2020OppenheimerReiterated RatingBuy$55.00High
5/7/2020HC WainwrightReiterated RatingBuy$50.00 ➝ $75.00High
5/6/2020OppenheimerInitiated CoverageBuy$55.00High
3/11/2020Robert W. BairdLower TargetOutperform$65.00 ➝ $55.00High
3/11/2020BMO Capital MarketsLower TargetIn-Line ➝ Market Perform$42.00 ➝ $35.00Low
3/11/2020CowenReiterated RatingBuyLow
2/13/2020SunTrust BanksInitiated CoverageBuy$50.00High
2/7/2020CowenInitiated CoverageOutperformHigh
1/9/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$43.00 ➝ $42.00High
12/10/2019OppenheimerBoost TargetOutperform$40.00 ➝ $55.00Low
12/10/2019HC WainwrightReiterated RatingBuy$50.00Low
12/10/2019Robert W. BairdReiterated RatingOutperform$35.00 ➝ $65.00High
11/7/2019Jefferies Financial GroupReiterated RatingIn-Line ➝ Buy$17.00 ➝ $40.00Medium
11/7/2019Royal Bank of CanadaBoost TargetOutperform ➝ Positive$42.00High
11/7/2019HC WainwrightBoost TargetBuy$18.00 ➝ $50.00High
11/6/2019OppenheimerBoost Target$18.00 ➝ $40.00High
9/4/2019Royal Bank of CanadaInitiated CoverageOutperform$20.00High
6/5/2019HC WainwrightReiterated RatingBuy$18.00Low
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Constellation Pharmaceuticals logo
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $33.99
Low: $33.99
High: $33.99

50 Day Range

MA: $33.89
Low: $33.63
High: $33.99

52 Week Range

Now: $33.99
Low: $17.00
High: $39.30

Volume

N/A

Average Volume

940,325 shs

Market Capitalization

$1.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Constellation Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Constellation Pharmaceuticals in the last year:
View the latest analyst ratings for CNST.

What is the current price target for Constellation Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Constellation Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Constellation Pharmaceuticals in the next year.
View the latest price targets for CNST.

What is the current consensus analyst rating for Constellation Pharmaceuticals?

Constellation Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CNST.

What other companies compete with Constellation Pharmaceuticals?

Other companies that are similar to Constellation Pharmaceuticals include Harmony Biosciences, Avadel Pharmaceuticals, Supernus Pharmaceuticals, Amneal Pharmaceuticals and Taro Pharmaceutical Industries. Learn More about companies similar to Constellation Pharmaceuticals.

How do I contact Constellation Pharmaceuticals' investor relations team?

Constellation Pharmaceuticals' physical mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company's listed phone number is 617-714-0555 and its investor relations email address is [email protected]. The official website for Constellation Pharmaceuticals is www.constellationpharma.com. Learn More about contacing Constellation Pharmaceuticals investor relations.